-
Je něco špatně v tomto záznamu ?
MicroRNA as an Early Biomarker of Neonatal Sepsis
M. Jouza, J. Bohosova, A. Stanikova, J. Pecl, O. Slaby, P. Jabandziev
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2013
Free Medical Journals
od 2013
PubMed Central
od 2013
Europe PubMed Central
od 2013
Open Access Digital Library
od 2013-01-01
Open Access Digital Library
od 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2013
PubMed
35615626
DOI
10.3389/fped.2022.854324
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Sepsis is a major cause of lethality in neonatal intensive care units. Despite significant advances in neonatal care and growing scientific knowledge about the disease, 4 of every 10 infants born in developed countries and suffering from sepsis die or experience considerable disability, including substantial and permanent neurodevelopmental impairment. Pharmacological treatment strategies for neonatal sepsis remain limited and mainly based upon early initiation of antibiotics and supportive treatment. In this context, numerous clinical and serum-based markers have been evaluated for diagnosing sepsis and evaluating its severity and etiology. MicroRNAs (miRNAs) do not encode for proteins but regulate gene expression by inhibiting the translation or transcription of their target mRNAs. Recently, it was demonstrated in adult patients that miRNAs are released into the circulation and that the spectrum of circulating miRNAs is altered during various pathologic conditions, such as inflammation, infection, and sepsis. Here, we summarize current findings on the role of circulating miRNAs in the diagnosis and staging of neonatal sepsis. The conclusions point to substantial diagnostic potential, and several miRNAs have been validated independently by different teams, namely miR-16a, miR-16, miR-96-5p, miR-141, miR-181a, and miR-1184.
Central European Institute of Technology Masaryk University Brno Czechia
Department of Biology Faculty of Medicine Masaryk University Brno Czechia
Department of Neonatology University Hospital Brno Brno Czechia
Department of Pediatrics University Hospital Brno Brno Czechia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017198
- 003
- CZ-PrNML
- 005
- 20220720100134.0
- 007
- ta
- 008
- 220718s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fped.2022.854324 $2 doi
- 035 __
- $a (PubMed)35615626
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Jouza, Martin $u Department of Pediatrics, University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
- 245 10
- $a MicroRNA as an Early Biomarker of Neonatal Sepsis / $c M. Jouza, J. Bohosova, A. Stanikova, J. Pecl, O. Slaby, P. Jabandziev
- 520 9_
- $a Sepsis is a major cause of lethality in neonatal intensive care units. Despite significant advances in neonatal care and growing scientific knowledge about the disease, 4 of every 10 infants born in developed countries and suffering from sepsis die or experience considerable disability, including substantial and permanent neurodevelopmental impairment. Pharmacological treatment strategies for neonatal sepsis remain limited and mainly based upon early initiation of antibiotics and supportive treatment. In this context, numerous clinical and serum-based markers have been evaluated for diagnosing sepsis and evaluating its severity and etiology. MicroRNAs (miRNAs) do not encode for proteins but regulate gene expression by inhibiting the translation or transcription of their target mRNAs. Recently, it was demonstrated in adult patients that miRNAs are released into the circulation and that the spectrum of circulating miRNAs is altered during various pathologic conditions, such as inflammation, infection, and sepsis. Here, we summarize current findings on the role of circulating miRNAs in the diagnosis and staging of neonatal sepsis. The conclusions point to substantial diagnostic potential, and several miRNAs have been validated independently by different teams, namely miR-16a, miR-16, miR-96-5p, miR-141, miR-181a, and miR-1184.
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bohosova, Julia $u Central European Institute of Technology, Masaryk University, Brno, Czechia
- 700 1_
- $a Stanikova, Andrea $u Faculty of Medicine, Masaryk University, Brno, Czechia $u Department of Neonatology, University Hospital Brno, Brno, Czechia
- 700 1_
- $a Pecl, Jakub $u Department of Pediatrics, University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
- 700 1_
- $a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Brno, Czechia $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czechia
- 700 1_
- $a Jabandziev, Petr $u Department of Pediatrics, University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia $u Central European Institute of Technology, Masaryk University, Brno, Czechia
- 773 0_
- $w MED00194312 $t Frontiers in pediatrics $x 2296-2360 $g Roč. 10, č. - (2022), s. 854324
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35615626 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220718 $b ABA008
- 991 __
- $a 20220720100129 $b ABA008
- 999 __
- $a ind $b bmc $g 1816480 $s 1168440
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 10 $c - $d 854324 $e 20220509 $i 2296-2360 $m Frontiers in pediatrics $n Front Pediatr $x MED00194312
- LZP __
- $a Pubmed-20220718